Pfizer will consider registering its vaccine in Russia

By | November 17, 2020
Pfizer will consider registering its vaccine in Russia

Pfizer will consider applying for registration of the COVID-19 vaccine created jointly with German BioNTech in Russia. It is planned to do this after receiving the necessary data on the results of clinical trials, the press service of Pfizer in Russia told “Interfax”.

Earlier Healthcare Minister Mikhail Murashko said that Pfizer had not applied to register a vaccine against COVID-19 in Russia. However, the agency will not oppose it. There are no contraindications to the registration of the Pfizer vaccine, the ministry told the agency.

Earlier Pfizer reported that during the third phase of the trial, which was attended by 40 thousand people, the vaccine showed more than 90% efficiency. The trials are not yet complete, but Pfizer plans to apply for registration of the vaccine for emergency use with the American regulator FDA. However, this vaccine has a serious disadvantage – it requires storage and transportation at minus 70 degrees, which is difficult to provide outside the rich countries with good medical infrastructure.

Yesterday, the U.S. company Moderna reported that as a result of the third phase of testing, the efficiency of its new coronavirus vaccine is more than 94 percent. At the same time, Moderna claims that it managed to increase the temperature of storage of the drug to minus 20 degrees.

Two vaccines are registered in Russia. They have been developed by the Gamaleya Center and the Vector scientific center of Rospotrebnadzor. Both vaccines were registered before the third stage of clinical trials was completed. This provoked criticism from Russian and foreign specialists. Another vaccine may be registered in Russia by the end of the year – the Chumakov Center development.

On November 11, the creators of the Russian vaccine Sputnik V reported the first results of the third phase of clinical trials. According to their claims, the efficiency was 92 percent. At the same time, the effect was assessed after the first dose of the two-component vaccine; the scientists did not explain this difference. At present, the vaccine “Sputnik V” is used to vaccinate risk groups: physicians, doctors, teachers.